Join a leading Notified Body Assessor, an Academic Engineering Expert, and a Former TUV SUD Assessor. Get a complete, practical roadmap covering everything from mechanical validation to clinical strategy and post-market evidence.
Organized by Eclevar MedTech
From pre-clinical testing to post-market compliance — get instant access to the recording and discover all three sessions below.
Enter your details to watch the replay immediately.
A deep dive into design, verification, and validation. Learn how to leverage physiological testing and rapid computational design assessments to optimise safety and meet the highest required testing standards.
Direct insights from a current SGS Assessor. Understand exactly what Notified Bodies expect for orthopaedic and spinal devices under the rigorous EU MDR frameworks, identifying red flags before submission.
Navigating the clinical evaluation and PMCF pathway. Discover how to build registries and post-market evidence programs that secure market access and guarantee long-term lifecycle compliance.
An exclusive convergence of regulatory assessment, academic engineering excellence, and specialized clinical operations.
A mechanical engineer running the Newell Spine Lab and Director of Metisec Ltd. Working at the intersection of academia and industry, Dr. Newell develops novel capability to test spinal devices physiologically and provides rapid computational design assessments.
Dr. Tavana serves as a Senior Product Assessor at SGS Belgium. Evaluating technical documentation directly from the Notified Body's perspective, he provides vital clarity on how the EU MDR is currently applied to complex orthopaedic technologies.
Having evaluated hundreds of clinical evidence packages at TUV SUD, Dr. Khadabadi builds PMCF programs and Clinical Evaluation Reports from the inside out, ensuring manufacturers navigate the MDR transition with absolute confidence.
Register now to secure your spot for this live expert panel. Bring your toughest questions regarding pre-clinical testing, clinical evidence, and regulatory hurdles.
